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Abstract
Background:  Conventional antipsychotics augmented with benzodiazepines have been the
standard acute treatment for psychiatric emergencies for more than 50 years. The inability of
patients to give informed consent limits randomised, controlled studies. This observational study
on immediate therapy for aggression and impulse control in acutely agitated patients (IMPULSE)
evaluated the short-term effectiveness and tolerability of atypical and typical antipsychotic
medications (AP) in a non-interventional setting.
Methods: This was a comparative, non-randomised, prospective, open-label, observational study.
Treatment over the first 5 days was classified according to whether any olanzapine, risperidone, or
haloperidol was included or not. Documentations (PANSS-excited component, CGI-aggression,
CGI-suicidality, tranquilisation score) were at baseline (day 1) and days 2–6 after start of AP.
Results: During the short treatment-period, PANSS-EC and CGI-aggression scores improved in
all cohorts. 68.7% of patients treated with olanzapine, 72.2% of patients treated with risperidone,
and 83.3% of patients treated with haloperidol received concomitant benzodiazepines (haloperidol
vs. non-haloperidol: p < 0.001). More patients treated with olanzapine (73.8%) were fully alert
according to a tranquilisation score and active at day 2 than patients treated with risperidone
(57.1%) or haloperidol (58.0%).
Conclusion: Current medication practices for immediate aggression control are effective with
positive results present within a few days. In this study, concomitant benzodiazepine use was
significantly more frequent in patients receiving haloperidol.
Background
Behavioural emergencies occur in approximately 1% to
20% of psychiatric patients admitted to hospitals and
necessitate physical restraint, seclusion and involuntary
(parenteral) medication [1-3]. Serious injuries to both
patients and staff can occur. However, the inability of
acutely agitated patients to give informed consent limits
the possibility to conduct randomised, controlled studies
evaluating the effectiveness of different treatment options
[2]. A non-interventional, observational study can over-
come these limitations.
For more than 50 years, conventional antipsychotics aug-
mented with benzodiazepines have been the standard
treatment [4,5]. The most important side-effects of acute
typical antipsychotic treatment are acute dystonic reac-
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tions, which can be both alarming and painful, but can be
avoided by using second-generation (atypical) antipsy-
chotics [6]. The objectives of this observational study were
to document immediate therapy (use of antipsychotic
medication and extent of concomitant benzodiazepine
use) for aggression and impulse control in acutely agitated
patients, and to evaluate the short-term effectiveness and
tolerability of atypical and typical antipsychotics (AP) in
this non-interventional setting (IMPULSE study).
Methods
Study design and population
The IMPULSE study was a non-randomised, non-inter-
ventional, open-label, prospective, multi-centre observa-
tional study in an unselected sample of patients with
behavioural emergencies. The study description asked for
patients with schizophrenia, meeting the following crite-
ria for participation: adult patients (≥ 18 years) newly
admitted to a psychiatric or forensic hospital, presenting
with agitation with or without aggression and requiring
antipsychotic treatment. Patients were recruited in Ger-
many between July 2003 and October 2004. Because this
was a non-interventional, observational study according
to German Drug Law (AMG) §67 (6), explicit ethical
approval by an institutional review board or written
patient consent was not required. The German Federal
Institute for Drugs and Medical Devices ("Bundesinstitut
für Arzneimittel und Medizinprodukte", BfArM) and the
German Statutory Health Insurance of Physicians ("Kas-
senärztliche Bundesvereinigung", KBV) were notified
about this observational study prior to the start of data
collection. Decisions on patient recruitment, the antipsy-
chotic treatment given and use or non-use of benzodi-
azepines were completely at the discretion of the
investigator. Due to the lack of randomisation and pre-
defined recruitment rules, patients receiving olanzapine
were over-represented when compared to the olanzapine
market share (IMS Health, approximately 30%) of antip-
sychotic agents in Germany during the recruitment period
in 2003–2004. Moreover, the investigators also recruited
patients with psychiatric disorders other than schizophre-
nia.
Assessments and measures
Assessments were carried out daily, at baseline (day 1)
and the following 5 days after initial documentation (days
2–6). Diagnoses were documented according to the Inter-
national Classification of Diseases, 10th revision (ICD-
10) [7]. The presence of comorbid substance use disorder
(SUD) was assessed according to ICD-10 criteria [7].
Psychiatric emergencies were categorised as follows: (i)
Self-endangering behaviour included acute suicidal
thoughts or plans, compulsatory admission because of
suicidality as well as self-injuring behaviour; (ii) Third
party endangering was defined to be present if patients
presented with one or more of the following symptoms:
intimidating behaviour, aggression to property, demean-
ing or hostile verbal behaviour, or aggression to persons;
(iii) Agitation was defined according to Lindenmayer [8]
as a state of poorly organised and aimless psychomotor
activity including symptoms such as motor restlessness,
heightened responsiveness to external or internal stimuli,
irritability, and/or decreased sleep.
Patients' antipsychotic treatment was categorised as
including any olanzapine or not (Olz or non-Olz),
including any risperidone or not (Ris or non-Ris), and
including any haloperidol or not (Hal or non-Hal). The
Olz, Ris, and Hal cohorts thus overlap, because each
cohort included all patients who received the respective
drug in any amount and at any time throughout the 5-day
study period.
Benzodiazepine dosages are presented as cumulative dose
during the complete study period, expressed as mg
diazepam equivalents. Those were calculated based on the
data published by Poser and Poser in 1996 [9].
The following instruments were completed at each visit:
Agitation was measured using the Excited Component of
the Positive and Negative Syndrome Scale (PANSS)
[10,11]. The PANSS-EC includes the following 5 items
from the PANSS, rated from 1 (not present) to 7
(extremely severe): poor impulse control, tension, hostil-
ity, uncooperativeness, and excitement (score range from
5 to 35; mean scores ≥ 20 clinically correspond with
severe agitation) [12]. PANSS-EC response rates were also
calculated, with response defined as ≥ 40% reduction
from baseline in PANSS-EC scores on day 6. Additional
instruments included the Clinical Global Impression
Severity of Illness – Aggression (CGI-A) and CGI-Suicidal-
ity (CGI-SS) Scales. The standard CGI scale [13,14] has
been adapted to measure severity of specific syndromes,
including aggression in patients with psychiatric disorders
(CGI-A) [15-17] and suicidality (CGI-SS) [18]. 5-point
likert scales were used for the CGI-A (1 = not at all aggres-
sive, 5 = aggressive behaviour) and the CGI-SS (1 = not at
all suicidal, 5 = attempted suicide). Finally, a single-item,
5-point tranquilisation scale (1 = fully alert and active, 5
= deeply asleep) was used to assess alertness of the
patients [19]. Treatment tolerability was assessed by
adverse event recording at each visit. Adverse events were
coded using the MedDRA classification system
Statistics
Based on market research data for the clinical setting from
January 2002 through January 2003, it was expected that
cohorts would contain at least 75 patients and up to
approximately 300 patients. Based on clinical trial data itBMC Psychiatry 2008, 8:61 http://www.biomedcentral.com/1471-244X/8/61
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was assumed that 43% to 53% of patients would receive
benzodiazepine co-medication, and the corresponding
two-sided 95% confidence intervals for these rates would
be approximately 11.2% (N = 75) and 5.6% (N = 300).
The standard deviations (SD) of mean daily benzodi-
azepine doses ranged from 3.2 mg to 5.8 mg in clinical
trial data. However, compared to clinical trials, a larger
standard deviation of daily benzodiazepine doses must be
assumed due to the naturalistic setting of the present
study. Assuming a SD of 7 mg leads to two-sided 95%
confidence intervals with a distance from mean to limit of
1.58 mg (N = 75) and 0.79 mg (N = 300). Therefore, the
planned total number of 500 patients was considered suf-
ficient to observe different therapeutic responses in a pop-
ulation of impulsive/aggressive patients with psychiatric
emergencies.
Due to the naturalistic and observational design of the
study, a specific primary outcome measure as required for
an interventional clinical trial was not defined; all analy-
ses were exploratory only. No confirmatory statistical tests
were performed, but 95% confidence intervals and p val-
ues were calculated for exploratory treatment group com-
parisons. Chi-square tests were used for categorical data, t-
tests with pooled variance were used for continuous data.
The odds ratios and the respective confidence intervals for
the use of benzodiazepines at any time were calculated by
cohort using the logistic regression technique. Except for
the PANSS-EC, all parameters were analyzed on a categor-
ical basis whereby each item at each time point was ana-
lyzed descriptively.
Results
Patient characteristics and disposition
A total of 558 patients with acute behavioural emergen-
cies were enrolled at 102 participating centres (median 5
patients per centre). Patient demographics are presented
in Table 1. More than 90% of patients (n = 523, 93.7%)
were assessed at psychiatric hospitals (forensic hospital
2.3%, missing data 3.9%). 390 patients (69.9%) received
at least one dose of olanzapine during the 5-day study
period and were therefore included in the olanzapine
(Olz) cohort. Of these, 177 patients suffered from schizo-
phrenia (n = 147) or manic episodes (n = 30), and were
therefore treated in-label. The remaining 30.1% of
patients were grouped in the non-olanzapine (non-Olz)
cohort. 132 patients (23.7%) received any haloperidol
(Hal), and 72 patients (12.9%) received any risperidone
(Ris).
Oral antipsychotic medication was used in the majority of
cases, but parenteral (intravenous or intramuscular) acute
or depot formulations were used as well. In the haloperi-
dol group (n = 132), 46 patients (34.9%) received intrave-
nous, 16 patients (12.1%) intramuscular and 7 patients
(5.3%) depot injections. In the olanzapine group (n = 389
with data available), 27 patients (6.9%) received an intra-
muscular preparation. In the risperidone group (n = 72),
5 patients (6.9%) each received intramuscular and depot
injections.
Most patients were diagnosed with schizophrenia spec-
trum disorders (n = 330, 59.1%). Other diagnoses and the
various types of psychiatric emergencies are presented in
Table 1. At baseline, only a small proportion of patients (n
= 9, 1.6%) had received prior treatment with anticholiner-
gics.
Almost all patients completed the 5 days study period
(97.4%); 1.2% of patients were lost to follow-up, 0.6%
discontinued due to adverse events, and 0.8% discontin-
ued due to other reasons.
Overall, 38.4% of patients had received prior antipsy-
chotic treatment (Table 2). Patients in the olanzapine
cohort were less frequently pre-treated with antipsychotics
than patients receiving no olanzapine (33.3% vs. 50.0%,
p < 0.001), while patients receiving risperidone were more
frequently pre-treated than those without risperidone
(52.8% vs. 36.2%, p = 0.007), and no difference was iden-
tified for the haloperidol versus non-haloperidol cohort.
No significant treatment group differences were identified
for prior benzodiazepine, mood stabilizer, or antidepres-
sive treatment.
During the study, the proportion of patients receiving
antipsychotic monotherapy was significantly higher in the
olanzapine than in the non-olanzapine cohort (46.9% vs.
26.2%, p < 0.001), but significantly lower in the risperi-
done vs. the non-risperidone and in the haloperidol vs.
non-haloperidol cohorts (p < 0.001, Table 2).
Overall, 389 patients (69.7%) received concomitant ben-
zodiazepine treatment, mostly lorazepam (n  = 248,
44.4%) or diazepam (n = 175, 31.4%). Table 2 presents
benzodiazepine treatment by treatment cohort. Mean
cumulative doses (in diazepam equivalents) over 5 days
tended to be lower in the olanzapine than in the non-
olanzapine cohort (77.9 mg vs. 89.0 mg, p = 0.081), no
differences were identified for the other cohorts. In the
olanzapine cohort, 68.7% of patients received any benzo-
diazepine treatment, as compared to 72.2% in the risperi-
done and 83.3% in the haloperidol cohorts. Patients in
the haloperidol cohort were treated with benzodiazepines
more frequently than those in the non-haloperidol
cohort: the odds-ratio for receiving any concomitant ben-
zodiazepines was 2.33 (95% CI: 1.39 – 3.85) for haloperi-
dol vs. non-haloperidol, as compared to 0.91 (95% CI:
0.60 – 1.37) for olanzapine vs. non-olanzapine and 1.12
(95% CI: 0.64 – 2.00) for risperidone vs. non-risperidone.BMC Psychiatry 2008, 8:61 http://www.biomedcentral.com/1471-244X/8/61
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Short-term effectiveness
PANSS-EC
Figure 1 presents the course of the PANSS-EC score from
baseline to endpoint for the olanzapine, risperidone and
haloperidol cohorts. At baseline, mean PANSS-EC scores
were 25 or higher, corresponding to a clinically severe agi-
tation syndrome. Up to the last day, PANSS-EC scores
decreased significantly over time in all treatment cohorts.
The percentage of patients classified as responders
(PANSS-EC ≥ 40% reduced) did not differ significantly
between treatment cohorts (Olz vs. non-Olz 70.0% vs.
66.7%, Ris vs. non-Ris 69.4% vs. 68.9%, Hal vs. non-Hal
71.2% vs. 68.3%, p > 0.5 for all comparisons).
CGI-aggression and CGI-suicidality scores
The proportion of patients who had at least a moderate
level of aggression (CGI-A score ≥ 3) decreased progres-
sively over the 5-day observation period, with no marked
differences between treatment groups (Figure 2). How-
ever, it must be noted that the olanzapine cohort tended
to have lower CGI-A ratings at baseline (CGI-A ≥ 3: Olz
73.3%, Ris 81.9%, Hal 80.3%).
Table 1: Patient demographics, diagnosis and characteristics by treatment cohort
Parameter [statistic] All patients Olanzapine vs. non-olanzapine Risperidone vs. non-risperidone Haloperidol vs. non-haloperidol
OLZ Non-OLZ RIS Non-RIS HAL Non-HAL
(N = 558) (N = 390) (N = 168) p-value (N = 72) (N = 486) p-value (N = 132) (N = 426) p-value
Patient demographics
Gender (male), n (%) 353
(63.3)
237
(60.8)
116
(69.0)
0.068 46
(63.9)
307
(63.2)
0.923 93
(70.5)
260
(61.0)
0.053
Age, median (range), y 38
(18–93)
37
(18–93)
39
(19–84)
0.068 40
(19–87)
38
(18–93)
0.081 39
(18–93)
38
(18–90)
0.223
Primary psychiatric diagnosisa
(ranked according to overall 
frequency)b
Schizophrenia spectrum disorders
(F20–F29), n (%)
330
(59.1)
215
(55.1)
115
(68.5)
0.003 50
(69.4)
280
(57.6)
0.057 92
(69.7)
238
(55.9)
0.005
Disorders due to substance use
(F10–F19), n (%)
98
(17.6)
69
(17.7)
29
(17.3)
0.902 7
(9.7)
91
(18.7)
0.061 23
(17.4)
75
(17.6)
0.962
Mood (affective) disorders
(F30–F39), n (%)
88
(15.8)
80
(20.5)
8
(4.8)
< .001 4
(5.6)
84
(17.3)
0.011 15
(11.4)
73
(17.1)
0.112
Disorders of adult personality and 
behaviour
(F60–F69), n (%)
84
(15.1)
67
(17.2)
17
(10.1)
0.032 10
(13.9)
74
(15.2)
0.767 4
(3.0)
80
(18.8)
< .001
Organic, including symptomatic 
mental disorders
(F00–F09), n (%)
69
(12.4)
39
(10.0)
30
(17.9)
0.010 14
(19.4)
55
(11.3)
0.051 19
(14.4)
50
(11.7)
0.418
Otherc, N (%) 57
(10.2)
43
(11.0)
14
(8.3)
0.335 8
(11.1)
49
(10.1)
0.788 5
(3.8)
52
(12.2)
0.005
Co-morbid substance use 
disorder (SUD) at baselineb
Nicotine, n (%) 241
(43.2)
172
(44.1)
69
(41.1)
0.507 28
(38.9)
213
(43.8)
0.430 50
(37.9)
191
(44.8)
0.159
Alcohol, n (%) 103
(18.5)
68
(17.4)
35
(20.8)
0.343 11
(15.3)
92
(18.9)
0.456 25
(18.9)
78
(18.3)
0.871
Illicit drugs, n (%) 83
(14.9)
59
(15.1)
24
(14.3)
0.798 9
(12.5)
74
(15.2)
0.544 24
(18.2)
59
(13.8)
0.222
Type of behavioural emergency 
at baselineb
Self-endangering, n (%) 264
(47.3)
186
(47.7)
78
(46.4)
0.784 28
(38.9)
236
(48.6)
0.125 68
(51.5)
196
(46.0)
0.268
Third party endangering, n (%) 393
(70.4)
266
(68.2)
127
(75.6)
0.079 57
(79.2)
336
(69.1)
0.082 108
(81.8)
285
(66.9)
0.001
Agitation, n (%) 408
(73.1)
294
(75.4)
114
(67.9)
0.066 53
(73.6)
355
(73.0)
0.919 98
(74.2)
310
(72.8)
0.739
Type of admission
Compulsory admission, n (%) 238
(42.7)
159
(40.8)
79
(47.0)
0.171 32
(44.4)
206
(42.4)
0.742 78
(59.1)
160
(37.6)
< .001
Premature discontinuation, n (%) 16
(2.9)
9
(2.3)
7
(4.2)
0.223 3
(4.2)
13
(2.7)
0.465 6
(4.5)
10
(2.3)
0.188
a ICD-10 diagnostic groups are listed according to the frequency among all patients.
b Patients may have received more than one ICD-10 diagnosis or more than one behavioural disturbance.
c Behavioural and emotional disorders with onset usually occurring in childhood and adolescence (F90–F98); behavioural syndromes associated with physiological disturbances 
and physical factors (F50–F59); neurotic, stress-related and somatoform disorders (F40–F48); and mental retardation (F70–F79)
Abbreviations: OLZ = olanzapine, RIS = risperidone, HAL = haloperidol.BMC Psychiatry 2008, 8:61 http://www.biomedcentral.com/1471-244X/8/61
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The proportion of patients rated at least moderately sui-
cidal (CGI-SS score ≥ 3) also decreased over the 5-day
observation period in all treatment cohorts (Figure 3).
Again, it must be noted that the olanzapine cohort tended
to have lower CGI-SS ratings at baseline (CGI-SS ≥ 3: Olz
20.3%, Ris 23.6%, Hal 23.7%).
Tranquilisation score
In all treatment cohorts, the percentage of patients rated
as "fully alert and active" (tranquilisation score = 1)
decreased from baseline to day 2 (Figure 4). However, the
proportion of patients who were still fully alert and active
on day 2 was markedly higher in the olanzapine cohort
(73.1%) than in the risperidone (55.6%) or haloperidol
(57.6%) cohorts. Over the remaining days of the observa-
tion, the percentage of fully alert and active patients grad-
ually increased again in all cohorts, and this percentage
remained highest in the olanzapine cohort on all post-
baseline days (Figure 4).
Tolerability
Treatment-emergent adverse events were reported in 37
patients (6.6%) of patients overall, the overall adverse
event rate was in the same order of magnitude for all treat-
ment cohorts (Table 3). The frequencies of specific
adverse events reported for the different treatment cohorts
are of limited validity due to the small numbers. However,
the adverse events reported most frequently in the olanza-
pine cohort were sedation, dizziness and weight gain (n =
3, 0.8% each). Dyskinesia (n = 3, 2.3%), extrapyramidal
disorder, sedation, and dizziness (n = 2, 1.5% each) were
reported most in the haloperidol cohort. In the risperi-
done cohort, no adverse event was reported more than
once. Serious adverse events were reported in four
patients; the investigator considered them as possibly
related to the primary AP medication in 2 patients (delir-
ium due to prescribed overdose [olanzapine 30–35 mg/d
for 2 days], related to olanzapine treatment; convulsions
of moderate severity, related to haloperidol treatment).
Two patients discontinued their AP due to adverse events
(olanzapine: the serious delirium event; risperidone: non-
serious dystonia).
Discussion
More than 4 million people are admitted to emergency
treatment facilities annually in the USA, in an acute con-
dition requiring immediate treatment to control aggres-
sive and impulsive behaviours [20]. Overall, these acutely
aggressive or impulsive patients account for more than
5% of all admissions to emergency treatment facilities in
Table 2: Treatment variables by treatment cohort
Parameter [statistic] All 
patients
Olanzapine vs. non-olanzapine Risperidone vs. non-risperidone Haloperidol vs. non-haloperidol
OLZ Non-OLZ RIS Non-RIS HAL Non-HAL
(N = 558) (N = 390) (N = 168) p-value (N = 72) (N = 486) p-value (N = 132) (N = 426) p-value
Previous pharmacological 
treatmenta
Any previous medication 
n (%)
291 (52.2) 191 (49.0) 100 (59.5) 0.022 45 (62.5) 246 (50.6) 0.060 64 (48.5) 227 (53.3) 0.335
Any antipsychotic n (%) 214 (38.4) 130 (33.3) 84 (50.0) < .001 38 (52.8) 176 (36.2) 0.007 52 (39.4) 162 (38.0) 0.778
Olanzapine, n (%) 52 (9.3) 48 (12.3) 4 (2.4) 5 (6.9) 47 (9.7) 13 (9.8) 39 (9.2)
Risperidone, n (%) 50 (9.0) 26 (6.7) 24 (14.3) 30 (41.7) 20 (4.1) 11 (8.3) 39 (9.2)
Haloperidol, n (%) 45 (8.1) 30 (7.7) 15 (8.9) 5 (6.9) 40 (8.2) 25 (18.9) 20 (4.7)
Quetiapine, n (%) 19 (3.4) 6 (1.5) 13 (7.7) 0 (0.0) 19 (3.9) 4 (3.0) 15 (3.5)
Any benzodiazepine n (%) 106 (19.0) 75 (19.2) 31 (18.5) 0.830 10 (13.9) 96 (19.8) 0.236 22 (16.7) 84 (19.7) 0.435
Lorazepam, n (%) 51 (9.1) 36 (9.2) 15 (8.9) 6 (8.3) 45 (9.3) 14 (10.6) 37 (8.7)
Diazepam, n (%) 43 (7.7) 29 (7.4) 14 (8.3) 3 (4.2) 40 (8.2) 7 (5.3) 36 (8.5)
Mood stabilizer n (%) 67 (12.0) 48 (12.3) 19 (11.3) 0.939 7 (9.7) 60 (12.3) 0.568 11 (8.3) 56 (13.1) 0.141
Antidepressants n (%) 64 (11.5) 47 (12.1) 17 (10.1) 0.679 8 (11.1) 56 (11.5) 0.976 9 (6.8) 55 (12.9) 0.056
Antipsychotic 
monotherapy n (%)
227 (40.7) 183 (46.9) 44 (26.2) < .001 13 (18.1) 214 (44.0) < .001 11 (8.3) 216 (50.7) < .001
Concomitant 
benzodiazepine use
Any benzodiazepine use n 
(%) [95% CI (%)]
389 (69.7) 
[65.7–73.5]
268 (68.7) 
[63.9–73.3]
121 (72.0) 
[64.6–78.7]
0.436 52 (72.2) 
[60.4–82.1]
337 (69.3) 
[65.0–73.4]
0.620 110 (83.3) 
[75.9–89.3]
279 (65.5)
[60.8–70.0]
< .001
Lorazepam, n (%) 248 (44.4) 177 (45.4) 71 (42.3) 35 (48.6) 213 (43.8) 65 (49.2) 183 (43.0)
Diazepam, n (%) 175 (31.4) 109 (27.9) 66 (39.3) 29 (40.3) 146 (30.0) 75 (56.8) 100 (23.5)
Other, n (%) 64 (11.5) 38 (9.7) 26 (15.5) 12 (16.7) 52 (10.7) 12 (9.1) 52 (12.2)
Benzodiazepine doseb
mean (SD), mg
81.3 (58.1) 77.9 (52.5) 89.0 (68.5) 0.081 86.4 (72.5) 80.6 (55.6) 0.497 76.4 (50.6) 83.3 (60.8) 0.296
a Patients may have received more than one previous pharmacological medication.
b Cumulative dose over the complete study period in mg diazepam equivalents.
Abbreviations: OLZ = olanzapine, RIS = risperidone, HAL = haloperidol.BMC Psychiatry 2008, 8:61 http://www.biomedcentral.com/1471-244X/8/61
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the USA [20]. In a 1995 study of emergency medical calls
in Hamburg, Germany, the treatment of aggressive or
impulsive patients was found to account for nearly 10% of
all calls for emergency physicians, and was the third most
common reason for such calls [21]. Given that emergency
treatment of such patients is so common and so urgent, it
is disappointing and surprising that no generally agreed-
upon guidelines exist for the emergency treatment of these
patients [22-24]. However, a number of factors have con-
tributed to the dearth of controlled clinical studies for the
treatment of acutely aggressive or impulsive patients.
The psychiatric sources of these behaviours, as well as the
physical and mental status of these patients at admission,
are extremely varied and are often unknown to the treat-
ing physician. For example, such patients may have a his-
tory of schizophrenia (accounting for approximately 21%
of visits to emergency treatment facilities in the USA [22]),
bipolar disorder, personality disorder, or other organic
disorder, and this population also typically includes users
(and abusers) of legal or illegal psychoactive substances
[25,26]. In our study, this fact is also reflected by a high
percentage of off-label use, e.g. less than 50% of the
patients within the olanzapine cohort were treated
according to the marketed indication. Also, the necessity
of treating these acutely aggressive and impulsive patients
immediately, often without time for a psychiatric or phys-
ical diagnosis, creates a need for antipsychotic medica-
tions that are rapidly effective, and safe for an extremely
disparate group of patients which may range from teenage
drug abusers to patients with Alzheimer's Disease.
Due to this urgency, combined with only scarce evidence
from controlled clinical studies, treating physicians gener-
ally rely upon older established medications (such as typ-
ical APs with or without concomitant benzodiazepines)
that may differ from more recently-introduced medica-
tions such as the atypical APs. Some controlled trials have
evaluated typical APs for emergency treatment, underlin-
ing their effectiveness. In one controlled, double-blind
study, an intramuscular injection of haloperidol and
CGI-agression (CGI-A) scores by antipsychotic treatment  cohort; percentage of patients with CGI-A scores ≥ 3 Figure 2
CGI-agression (CGI-A) scores by antipsychotic treat-
ment cohort; percentage of patients with CGI-A 
scores ≥ 3. Note: Patients in the olanzapine, risperidone and 
haloperidol cohorts may overlap because all olanzapine, risp-
eridone, or haloperidol patients are included who received at 
least one dose of the respective drug. Abbreviations: OLZ = 
olanzapine, RIS = risperidone, HAL = haloperidol.Figure leg-
end text.
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Course of PANSS-excited component (PANSS-EC) scores  (means and standard deviations) by antipsychotic treatment  cohort Figure 1
Course of PANSS-excited component (PANSS-EC) 
scores (means and standard deviations) by antipsy-
chotic treatment cohort. Note: Patients in the olanzap-
ine, risperidone and haloperidol cohorts may overlap 
because all olanzapine, risperidone, or haloperidol patients 
are included who received at least one dose of the respective 
drug. Abbreviations: OLZ = olanzapine, RIS = risperidone, 
HAL = haloperidol. Last obs = last observation.
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lorazepam was more rapid in achieving emergency tran-
quilisation than either haloperidol or lorazepam alone
[5]. Two large pragmatic, randomised studies conducted
in India and Brazil have evaluated intramuscular
haloperidol-promethazine combination treatment, a
standard treatment for patients in these countries, versus
a rapid-acting intramuscular benzodiazepine (mida-
zolam, lorazepam) [27,28]. Both interventions were effec-
tive in controlling agitated behaviour; however,
midazolam was more rapidly sedating than haloperidol-
promethazine in one study [27], while lorazepam was act-
ing slower than haloperidol-promethazine in the other
study [28]. One recent double-blind controlled study
showed greater efficacy of the atypicals clozapine and
olanzapine versus haloperidol in reducing aggressive
behaviour in long-term management of inpatients [29].
However, carefully-controlled clinical studies of atypicals
versus typicals for emergency treatment are scarce, but a
number of comprehensive literature reviews have con-
cluded that the atypical APs are at least as effective and
generally have better tolerability than the typical APs
administered with or without benzodiazepines
[3,22,23,30]. For example, in a double-blind comparison
of olanzapine versus the benzodiazepine lorazepam for
treatment of acute psychiatric episodes, olanzapine treat-
ment was found equally effective and with a better tolera-
bility profile, particularly with respect to the incidence of
EPS [31,32].
Another reason for the paucity of controlled clinical trials
in patients with acute aggressive or impulsive behaviour is
that until recently most atypical APs were not available as
intramuscular formulations [3], which many physicians
prefer for acute treatment of aggressive patients. However,
intramuscular formulations of ziprasidone and olanzap-
ine are now available, and results from controlled studies
indicated that these are equally effective and fast-acting as
the commonly-used intramuscular formulations of APs
[30-33]. In addition, a fast-dissolving oral formulation of
olanzapine has recently been developed [34,35] and has
proven effective in patients requiring acute treatment.
Tranquilisation score by antipsychotic treatment cohort; per- centage of patients fully alert and active Figure 4
Tranquilisation score by antipsychotic treatment 
cohort; percentage of patients fully alert and active. 
Note: Patients in the olanzapine, risperidone and haloperidol 
cohorts may overlap because all olanzapine, risperidone, or 
haloperidol patients are included who received at least one 
dose of the respective drug. Abbreviations: OLZ = olanzap-
ine, RIS = risperidone, HAL = haloperidol.
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CGI-suicidality (CGI-SS) scores by antipsychotic treatment  cohort; percentage of patients with CGI-SS scores ≥ 3 Figure 3
CGI-suicidality (CGI-SS) scores by antipsychotic 
treatment cohort; percentage of patients with CGI-
SS scores ≥ 3. Note: Patients in the olanzapine, risperidone 
and haloperidol cohorts may overlap because all olanzapine, 
risperidone, or haloperidol patients are included who 
received at least one dose of the respective drug. Abbrevia-
tions: OLZ = olanzapine, RIS = risperidone, HAL = haloperi-
dol.
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The current IMPULSE study investigated treatment of
acutely agitated patients including the short-term effec-
tiveness and tolerability of olanzapine and other antipsy-
chotic treatments (risperidone, haloperidol). The
observational nature of this study enabled the inclusion
of a highly agitated, heterogeneous group of patients,
many of whom would have normally been excluded from
randomised trials with strict in- and exclusion criteria.
Thus, the results of this study are more representative of
those patients generally encountered in an emergency
treatment situation. However, as for all observational
studies, the lack of randomisation and of independent,
blinded assessments are clear limitations of this study. For
this study in particular, it needs to be considered that
patients receiving olanzapine treatment were over-repre-
sented in our population compared to the olanzapine
market share, limiting the generalisability and representa-
tivity of our results. Furthermore, treatment groups were
not fully comparable due to the lack of randomisation.
Patients in the olanzapine cohort were less frequently pre-
treated with antipsychotics than patients receiving no
olanzapine, while patients receiving risperidone were
more frequently pre-treated. Also, the olanzapine cohort
tended to have lower CGI-A and CGI-SS ratings at base-
line. These differences indicate that the olanzapine cohort
may represent somewhat less severe patients at baseline.
Patients' psychiatric diagnoses and other background
characteristics were quite varied, and should be reflecting
the wider population of patients requiring immediate
treatment for aggression: mean patient age was 40 years,
about 63% were male, and large percentages abused psy-
choactive substances such as nicotine, alcohol, and/or
illicit drugs. Large percentages of these patients were con-
sidered to be self-endangering or endangering to others,
showed psychomotor agitation, or their behaviour
required compulsory admission to a hospital or clinic. A
majority of the patients in this study had an ICD-10 diag-
nosis of schizophrenia (F20–F29), and large proportions
had mental disorders due to psychoactive substance abuse
(F10–F19), mood disorders (F30–F39), or adult personal-
ity disorders (F60–F69).
About 70% of the patients (147 suffering from schizo-
phrenia, 30 from manic episodes, and 213 with other
diagnoses) in this study received at least one dose of olan-
zapine during the 5-day treatment and observation
period, usually in combination with other APs. The
remaining 30% were treated with APs other than olanza-
pine. The proportion of patients receiving antipsychotic
polytherapy was much lower in the olanzapine than in
the risperidone or haloperidol cohorts. However, these
data may have been biased by the observational and non-
randomised study design and the associated over-repre-
sentation of olanzapine-treated patients.
Overall, about 70% of patients did receive benzodi-
azepines in addition to the AP medications. However,
benzodiazepine use was numerically lower in the olanza-
pine-treated patients than in those receiving risperidone
or haloperidol, and daily benzodiazepine doses were
numerically lower in patients receiving haloperidol or
olanzapine than in those receiving risperidone.
For the analyses used in this study, all treatment groups
showed clear improvements of effectiveness measures
Table 3: Adverse events
Event, MedDRA preferred term All patients Olanzapine Non-Olanzapine Risperidone Non-Risperidone Haloperidol Non-Haloperidol
(N = 558) (N = 390) (M = 168) (N = 72) (N = 486) (N = 132) (N = 426)
Treatment-emergent adverse 
events, n (%)
37 (6.6) 24 (6.2) 13 (7.7) 8 (11.1) 29 (6.0) 13 (9.8) 24 (5.6)
Dyskinesiaa, n (%) 4a (0.7) 2 (0.5) 2 (1.2) 0 (0.0) 4 (0.8) 3 (2.3) 1 (0.2)
Extrapyramidal disorder, n (%) 4 (0.7) 1 (0.3) 3 (1.8) 1 (1.4) 3 (0.6) 2 (1.5) 2 (0.5)
Sedation, n (%) 4 (0.7) 3 (0.8) 1 (0.6) 1 (1.4) 3 (0.6) 2 (1.5) 2 (0.5)
Dizziness postural, n (%) 3 (0.5) 3 (0.8) 0 (0.0) 0 (0.0) 3 (0.6) 2 (1.5) 1 (0.2)
Weight increased, n (%) 3 (0.5) 3 (0.8) 0 (0.0) 1 (1.4) 2 (0.4) 0 (0.0) 3 (0.7)
Akathisia, n (%) 2 (0.4) 2 (0.5) 0 (0.0) 1 (1.4) 1 (0.2) 0 (0.0) 2 (0.5)
Oculogyric crisis, n (%) 2 (0.4) 2 (0.5) 0 (0.0) 1 (1.4) 1 (0.2) 0 (0.0) 2 (0.5)
Salivary hypersecretion, n (%) 2 (0.4) 1 (0.3) 1 (0.6) 1 (1.4) 1 (0.2) 0 (0.0) 2 (0.5)
Adverse events considered related to 
primary AP medication, n (%)
33 (5.9) 21 (5.4) 12 (7.1) 8 (11.1) 25 (5.1) 12 (9.1) 21 (4.9)
Serious adverse events, n (%) 4 (0.7) 2 (0.5) 2 (1.2) 0 (0.0) 4 (0.8) 3 (2.3) 1 (0.2)
Serious adverse events considered 
related to primary AP medication, n 
(%)
2 (0.4) 1 (0.3) 1 (0.6) 0 (0.0) 2 (0.4) 2 (1.5) 0 (0.0)
Clinically significant adverse events 
resulting in discontinuation, n (%)
2 (0.4) 1 (0.3) 1 (0.6) 1 (1.4) 1 (0.2) 0 (0.0) 2 (0.5)
Only preferred terms occurring in at least 2 patients are listed.
Patients may be included in more than one category of event or preferred term.
a Includes the following original terms as reported by physicians: early dyskinesias (n = 3), perioral dyskinesia (n = 1).BMC Psychiatry 2008, 8:61 http://www.biomedcentral.com/1471-244X/8/61
Page 9 of 10
(page number not for citation purposes)
even within the short observation time of this study. The
PANSS-EC and CGI-aggression and CGI-suicidality scores
improved to a comparable extent in the olanzapine, risp-
eridone and haloperidol treatment groups. Nearly all
patients were alert and active at the baseline measurement
of the tranquilisation score. Patients in the olanzapine
cohort were less sedated than the risperidone or haloperi-
dol cohorts on all post-baseline days. This difference was
most pronounced on day 2. This positive effect observed
in the olanzapine cohort may have been caused by less
frequent use of concomitant benzodiazepines, suggesting
that olanzapine may achieve an effective immediate con-
trol of aggression without severe tranquilisation of the
patient. Intake of lower amounts of benzodiazepines can
be expected to reduce the incidence of adverse effects asso-
ciated with benzodiazepines (e.g., sedation, ataxia, confu-
sion, and respiratory depression), and reduce the
incidence of adverse events caused by interactions
between benzodiazepines and other antipsychotic medi-
cations. However, the limitations due to the observational
and non-randomised study design need to be considered
when evaluating these results.
Conclusion
Immediate control of aggressive and impulsive behaviour
can be effectively achieved through administration of
antipsychotic medications, which are often administered
without knowing the definite diagnosis in this specific set-
ting. During the course of this short-term study, improve-
ments in CGI-A and PANSS-EC were similar for
olanzapine, risperidone and haloperidol treatment. The
odds for receiving antipsychotic monotherapy were
higher in patients treated with olanzapine. Compared to
patients treated exclusively with other APs, those receiving
olanzapine as antipsychotic monotherapy or part of com-
bination treatment experienced a numerical reduction
(not significant in exploratory statistical analysis) of ben-
zodiazepine use and a positive effect on tranquilisation in
the present non-randomised, naturalistic study. In
patients receiving haloperidol, concomitant benzodi-
azepine use was significantly more frequent than in
patients not treated with haloperidol. Given the huge
number of patients requiring emergency inpatient or out-
patient treatment for aggressive or impulsive behaviour,
the use of atypical antipsychotics such as olanzapine may
have the potential to reduce the medical burden for
patients with this psychiatric condition.
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